BRIEF published on 10/30/2024 at 17:50, 21 days 19 hours ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
BRIEF published on 10/07/2024 at 17:50, 1 month 13 days ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
BRIEF published on 09/06/2024 at 17:50, 2 months 14 days ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 2 months 14 days ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 2 months 16 days ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 2 months 16 days ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 2 months 22 days ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 4 months 2 days ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 4 months 2 days ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
BRIEF published on 06/07/2024 at 17:50, 5 months 13 days ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
Published on 11/21/2024 at 13:00, 32 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 32 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 32 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 32 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 32 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 57 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 17 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 34 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 12 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 47 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 47 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
